<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191020</url>
  </required_header>
  <id_info>
    <org_study_id>XijingH-PF-20120909</org_study_id>
    <nct_id>NCT02191020</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Total Glucosides of Paeony Combined With Acitretin to Treat Psoriasis</brief_title>
  <official_title>Multi-center, Randomized, Double Blind, Placebo Parallel-Controlled Study of the Efficacy and Safety of Total Glucosides of Paeony Combined With Acitretin Capsules to Treat Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, placebo parallel-controlled, multi-center clinical trial.&#xD;
      Patients with psoriasis vulgaris were randomly divided into the experiment group （treated&#xD;
      with TGP combined with acitretin capsules) and control group （treated with placebo combined&#xD;
      with acitretin capsules）.The treatment lasted 12 weeks. The efficacy and safety were&#xD;
      evaluated at the baseline, as well as 2, 4, 8 and 12 weeks after the beginning of&#xD;
      treatment.The investigator's hypothesis TGP combined with Acitretin Capsulesin is more safe&#xD;
      and effective than Acitretin Capsulesin to treat Psoriasis Vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Psoriasis Area and Severity Index</measure>
    <time_frame>week 0 and week 12</time_frame>
    <description>After 12 weeks treatment, relative to baseline, the proportion of patients achieving a 50% reduction in Psoriasis Area and Severity Index 50 (PASI50) was 90% in the experiment group and 70.5% in the control group (P&lt;0.05).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of elevated Alanine aminotransferase</measure>
    <time_frame>week 0 and week12</time_frame>
    <description>After 12 weeks treatment, relative to baseline,the incidence of elevated Alanine aminotransferase (ALT) was 6.8% in the experiment group and 22.2% in the control group (P&lt;0.05).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Total glucosides of paeony &amp; Acitretin Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the first week，0.6g，oral，b.i.d.During the other weeks，0.6g，oral，t.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acitretin Capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mg/day oral,when subject's weight less than 70kg;otherwise,30mg/day oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Total glucosides of paeony &amp; Acitretin Capsules</intervention_name>
    <arm_group_label>Total glucosides of paeony &amp; Acitretin Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acitretin Capsules</intervention_name>
    <arm_group_label>Acitretin Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Meet the following conditions&#xD;
&#xD;
          1. Diagnosed according to Classification criteria for Psoriasis vulgaris;&#xD;
&#xD;
          2. Patients aged 18 to 65 years (to the date of screening);&#xD;
&#xD;
          3. PASI grade&gt;7point&lt;20 point;&#xD;
&#xD;
          4. Not treatment in the Topical corticosteroids、Immunosuppresso、Biologicals agents or&#xD;
             Tretinoin cream、Phototherapy nearly one months before enrolled.&#xD;
&#xD;
          5. Understanding the whole process of the study, voluntary participation and signed the&#xD;
             informed consent;&#xD;
&#xD;
          6. Patient compliance is good, can guarantee in course of observation.&#xD;
&#xD;
        Exclusion Criteria:One of the following is not included in this study:&#xD;
&#xD;
          1. Pregnant women, ready to pregnant or lactating women;&#xD;
&#xD;
          2. Known to root of herbaceous peony total glycosides (TGP) drug allergy;&#xD;
&#xD;
          3. Have a serious heart, lung, kidney and other vital organs and endocrine system lesions&#xD;
             and the history&#xD;
&#xD;
          4. Patients is liver function abnormal persons (ALT above the center laboratory normal&#xD;
             limit) or hepatitis b patient grain carriers;&#xD;
&#xD;
          5. Need insulin control of diabetes; High blood pressure did not get good controller ;&#xD;
&#xD;
          6. Patients with white blood cells &lt;4.0 × 109 / L, or a definite anemia (hemoglobin less&#xD;
             than 100g / L), or platelets &lt;100 × 109 / L, or other blood disease;&#xD;
&#xD;
          7. Patients with chronic diarrhea, or peptic ulcer nearly 1 year;&#xD;
&#xD;
          8. Patients suffering from malignant tumor;&#xD;
&#xD;
          9. Patients suffering from acute and chronic infectious diseases;&#xD;
&#xD;
         10. Mental disorders, history of alcohol abuse, drug or other substance abuse; 11. Other&#xD;
             cases which researchers believe that can not enroll.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hospitial</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>January 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>xjpfW</investigator_full_name>
    <investigator_title>Chief in Department of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Total Glucosides of Paeony(TGP)</keyword>
  <keyword>Acitretin Capsules</keyword>
  <keyword>Psoriasis Vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acitretin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

